I believe the technology works from what I've heard and read about CaverStem, FemCelz, AmnioStem and StemSpine and the research they've conducted. Patents CMTH holds hold promise. All this needs to transform into sustainable revenue.
CMTH's communication skills need to improve.
CMTH does need a forceful impact statement of operations along with honest evaluation/assessment and disclosure concerning any existing and extended business plans they may have that can be measured in anticipated revenues for shareholders. Plain and simple ... shareholders deal in numbers that we can see and trust.
Notes do need to be refinanced without loan shark lenders, toxic or spiral financing. Will there be enough revenue to extinguish notes? <<< Management answer this.
Anticipation is one thing we've (as shareholders) have been well exposed for over two years, however, shareholders expect CMTH's performance to pay off and produce sufficient and significant numbers not only to fund existing costs but to pay off those notes.
CMTH, please let us know what type of refinancing your existing notes and future financing notes will be. Give us good financial reasons to invest in CELZ/CELZD.
CMTH definitely needs to expand their base of physicians in areas currently not served in the United States. I can understand the Southwest area being served as their proximity to CMTH is pretty close. Although Florida, Hawaii and a clinic in Italy serve clients, there lacks market presence in the Northwest, Mid and Upper West, Northeast and mid-Atlantic.
Hopefully some of these new physicians coming aboard will begin to disperse for easier client access. Hopefully CMTH will exceed revenues quarter over quarter by significant numbers.
Yes, CMTH needs improvement, no question about it in my view. We shall see.
News 
Market Data 
Discover 
